OakChart

Mesoblast Ltd ADR

MESOHealthcare·Biotechnology·Australia·Small·NASD·Nov 11 • 1:19 PM ET

13.76-0.23 (-1.66%)
2026-11-11 19:21 CET
Market cap
1,820.24 USD m
Revenue, TTM
120.57 USD m
Net income, TTM
-57.63 USD m
Free cash flow, TTM
-68.00 USD m
EPS diluted, TTM
-0.45
P/E
-
Compare

Price

MESO against its 20, 50 and 200-day averages
2050200earnings
12.0014.0016.0018.00475K951KMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26MESOclose 13.7620-day 13.6650-day 14.48200-day 15.2613.7652w low

36.0% under the 52-week high of 21.50 on 9 Jan 2026. 52-week low 11.89 on 19 Oct 2026. Last 15 sessions, 29.6% high to low

Profile

MESO
52-week range, 19% of the way up
11.8921.50

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Silviu Itescu on June 8, 2004 and is headquartered in Melbourne, Australia.

Employees108
IPOJan 18, 2006
Beta2.23
ATR, 14d0.66
Rel volume0.28
Short float2.79%
Inst own2.99%

Snapshot

6 groups

Valuation

Index-
Market Cap1.79B
Enterprise Value1.81B
Income-57.63M
Sales120.57M
Book/sh4.38
Cash/sh0.79
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees108
IPOJan 18, 2006

Ratios

P/E-
Forward P/E53.71
PEG-
P/S14.85
P/B3.14
P/C17.39
P/FCF-
EV/EBITDA-
EV/Sales15.05
Quick Ratio2.09
Current Ratio2.43
Debt/Eq0.22
LT Debt/Eq0.20
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.45
EPS next Y0.26
EPS next Q-0.08
EPS this Y64.45%
EPS next Y262.31%
EPS next 5Y-
EPS past 3/5Y24.72% 22.09%
Sales past 3/5Y152.90% 74.52%
EPS Y/Y TTM47.33%
Sales Y/Y TTM600.89%
EPS Q/Q12.33%
Sales Q/Q-5.36%
EarningsAug 26 AMC
EPS/Sales Surpr.-23.98% -6.61%

Ownership

Insider Own-
Insider Trans-
Inst Own2.99%
Inst Trans-19.40%
ROA-7.40%
ROE-9.89%
ROIC-8.45%
Gross Margin84.10%
Oper. Margin-42.63%
Profit Margin-47.80%
SMA200.72%
SMA50-5.00%
SMA200-9.84%
Trades-

Technical

Shs Outstand130.11M
Shs Float128.29M
Short Float2.79%
Short Ratio14.91
Short Interest3.58M
52W High21.50 -36.01%
52W Low11.89 15.71%
Volatility4.54% 3.68%
ATR (14)0.66
RSI (14)47.11
Beta2.23
Rel Volume0.28
Avg Volume239.93K
Volume41,513

Performance

Perf Week-3.72%
Perf Month-0.98%
Perf Quarter-16.57%
Perf Half Y-6.60%
Perf YTD-23.73%
Perf Year-11.41%
Perf 3Y459.28%
Perf 5Y13.33%
Perf 10Y47.94%
Recom1.00
Target Price30.21
Prev Close13.99
Price13.76
Change %-1.66%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Nov 25, 2025UpgradeJJefferiesHold → Buy
Jul 18, 2025DowngradeJJefferiesBuy → Hold
Dec 23, 2024DowngradeJJefferiesBuy → Hold
Sep 24, 2024UpgradeMMaxim GroupHold → Buy$12-12.8%
Aug 29, 2024UpgradeJJefferiesHold → Buy
Jul 23, 2024UpgradePPiper SandlerNeutral → Overweight$4 → $11-20.0%
Aug 31, 2023UpgradeJJefferiesHold → Buy
Aug 07, 2023DowngradeMMaxim GroupBuy → Hold
Aug 04, 2023DowngradeWWilliam BlairOutperform → Mkt Perform
Aug 04, 2023DowngradePPiper SandlerOverweight → Neutral$7 → $2-85.5%

Peers

Mkt cap
TickerCompanyMkt cap
VCELVericel Corp2.98B
SNDXSyndax Pharmaceuticals Inc869.58M
INCYIncyte Corp24.88B
CAPRCapricor Therapeutics Inc613.65M
LCTXLineage Cell Therapeutics Inc280.72M
PLURPluri Inc15.51M
IOVAIovance Biotherapeutics Inc3.76B
CRSPCRISPR Therapeutics AG4.44B
BCDABioCardia Inc13.89M
BRTXBioRestorative Therapies Inc2.08M

Insider trading

6 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
George GregoryDirectorApr 04 '26Buy1.424,000,0005,680,00012,000,000Apr 13 07:19 AM
George GregoryDirectorApr 10 '26Buy1.482,324,0723,439,6278,324,072Apr 13 07:19 AM
George GregoryDirectorApr 09 '26Buy1.441,586,8902,277,35013,586,890Apr 13 07:19 AM
George GregoryDirectorApr 09 '26Buy8.591,981,89017,015,46713,586,890Apr 10 07:27 PM
George GregoryDirectorApr 04 '26Buy1.424,000,0005,680,00012,000,000Apr 10 07:27 PM
George GregoryDirectorApr 10 '26Buy1.482,324,0723,439,6278,324,072Apr 10 07:27 PM

Held by

AUM
TickerCompanyAUM
IBBiShares Biotechnology ETFAUM: 11.36B
APIEActivePassive International Equity ETFAUM: 1.13B
QQQSInvesco NASDAQ Future Gen 200 ETFAUM: 20.53M
IBBQInvesco Nasdaq Biotechnology ETFAUM: 130.27M
BIBProShares Ultra Nasdaq Biotechnology 2X SharesAUM: 107.35M

News

latest 14 of 200
  • Use Of Ryoncil First Line After Steroids For Pediatric Acute Graft Versus Host Disease Highlighted In Key Opinion Leader Webinar (GlobeNewswire)
  • Mesoblast Board Changes (GlobeNewswire)
  • Inside Biotech: Mesoblast surges 24% as Ryoncil sales climb and cash spend falls sharply (Proactive) +17.03%
  • Activity Report for Quarter Ended September 30, 2026 (Appendix 4C) (GlobeNewswire)
  • Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product (GlobeNewswire)
  • Mesoblast Reports Substantial Revenue Growth to US$120M (GlobeNewswire) +7.96%
  • Mesoblast Financial Results and Corporate Update Webcast (GlobeNewswire)
  • Mesoblast shares jump as Phase 3 chronic back pain trial completes patient treatment (InvestorsHub) +9.14%
  • Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain (GlobeNewswire)
  • Mesoblast Reports Ryoncil Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch (GlobeNewswire)
  • Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain (GlobeNewswire) +5.05%
  • Ryoncil Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026 (GlobeNewswire)
  • Mesoblast Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADs (GlobeNewswire)
  • Mesoblast Draws US$50 Million from Five-Year Non-Dilutive Facility (GlobeNewswire) -6.75%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026S22026-08-26-0.131-0.106-0.13469.0773.964
2026S12026-02-26-0.311-0.237-0.31151.3453.064
2025S22025-08-28-0.427-0.373-0.42614.0614.133
2025S12025-02-26-0.420-0.490-0.4203.202.982
2025Q12024-11-20-0.140-0.140-0.1401.491.491
2024S22024-08-28-0.521-0.353-0.5092.514.103
2024S12024-02-28-0.382-0.427-0.3823.393.872
2023S22023-08-30-0.512-0.599-3.905.991
2023Q32023-05-25-0.253-0.332-0.2391.942.145
2023Q22023-02-27-0.332-0.360-0.3152.132.104
2023Q12022-11-22-0.243-0.327-0.2281.503.473
2022Q42022-08-31-0.340-0.205-0.3132.2610.094
2022Q32022-06-01-0.328-0.270-0.3122.012.104
2022Q22022-02-24-0.400-0.407-0.3802.383.503
2022Q12021-11-23-0.349-0.385-0.3312.402.354
2021Q42021-08-30-0.320-0.195-0.3212.0017.714

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-1.398-1.168-1.39732.1644.18
2021FY-1.548-1.320-1.5547.5027.23
2022FY-1.335-1.062-1.33510.2113.89
2023FY-1.051-1.076-1.0467.508.41
2024FY-0.891-0.523-0.8955.907.49
2025FY-0.846-0.590-0.84417.2017.52
2026FY-0.444-0.439-0.444120.25125.31
2027FY--0.158--196.1
2028FY-0.256--347.67
2029FY-1.189--700.33
2030FY-3.195--885.89
2031FY-5.035--1,290

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2027S1S2026-11-1050376.6162.2597.30
2027S1S2026-10-2951476.6162.2597.30
2027S1S2026-10-1951479.3162.2597.30
2027S1S2026-10-1651381.3162.2597.30
2027S1S2026-10-1551286.2362.25109.4
2027S1S2026-10-1451286.2362.25109.4
2027S1S2026-09-2351187.9570.81109.4
2027S1S2026-09-2251187.8970.81109.4
2027S1S2026-08-2752187.8970.81109.4
2027S1S2026-08-0441082.1271.4098.60
2027S1S2026-07-2131083.8371.4098.60
2027S1S2026-07-1831083.8271.3898.60
2027S1S2026-07-1041082.1271.3898.60
2027S1S2026-07-0931076.6271.3881.49

Estimate history

EPS, annual-0.719-1.722-1.397-1.554-1.335-1.046-0.895-0.844-0.446
Period201820192020202120222023202420252026
EPS, quarterly-0.228-0.315-0.239
PeriodQ1 '23Q2 '23Q3 '23
Sales, annual16.97516.00331.6147.46210.2117.4675.92417.169120.787
Period201820192020202120222023202420252026
Sales, quarterly1.4862.1341.939
PeriodQ1 '23Q2 '23Q3 '23
Shares, annual50.53452.2261.21968.33668.54585.816114.124127.993129.666
Period201820192020202120222023202420252026
Shares, quarterly77.68677.68677.686
PeriodQ1 '23Q2 '23Q3 '23

Income statement, annual

Currency USD, millions
MetricTTM2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue120.57120.7917.175.927.4710.217.4631.6116.00
Cost of Goods Sold Incl. D&A19.1819.2111.5115.7727.6130.7632.8425.3115.36
Gross Profit101.39101.585.66-9.85-20.14-20.55-25.386.300.65
Selling, General and Administrative Excl. Other152.79153.0867.6049.1652.3360.0284.1981.8081.51
Research and Development97.7697.9434.7525.4527.0732.8153.2156.1959.89
Other Operating Expense0.000.000.480.040.000.000.000.00-
Operating Income-51.39-51.50-62.42-59.05-72.47-80.57-109.57-75.49-80.87
Interest Expense23.8923.9522.9323.0920.0317.2916.0014.7211.70
Unusual Expense-13.34-13.3619.828.95-6.61-6.81-24.00-1.996.64
Net Income Before Taxes-57.01-57.14-101.72-89.33-85.22-91.59-100.00-87.36-98.75
Income Taxes0.610.620.25-1.05-3.70-0.24-0.82-9.41-8.96
Consolidated Net Income-57.63-57.76-101.97-88.28-81.52-91.35-99.18-77.94-89.80
Net Income From Continuing Operations-57.63-57.76-101.97-88.28-81.52-91.35-99.18-77.94-89.80
Net Income-57.63-57.76-101.97-88.28-81.52-91.35-99.18-77.94-89.80
EPS (Recurring)-0.52-0.52-0.73-0.83-1.11-1.40-1.82-1.42-1.63
EPS (Basic, Before Extraordinaries)-0.45-0.45-0.84-0.89-1.05-1.33-1.55-1.40-1.72
EPS (Diluted)-0.45-0.45-0.84-0.89-1.05-1.33-1.55-1.40-1.72
EBITDA-42.79-42.88-56.03-54.36-68.38-76.19-105.29-71.83-78.73
Non-Operating Income (Expense)4.934.943.451.750.66-0.541.570.870.46
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense10.4410.4615.444.122.553.888.795.273.06
Price To Sales Ratio14.5514.5076.61113.4377.1228.12120.8837.9732.69
Gross Margin84.1084.0932.96-166.30-269.72-201.21-340.1319.944.03
Operating Margin-42.63-42.64-363.58-996.80-970.47-789.06-1,468.44-238.79-505.34
Net Margin-47.80-47.82-593.92-1,490.27-1,091.71-894.59-1,329.18-246.54-561.14
Shares Outstanding129.67129.67127.99114.1285.8268.5568.3461.2252.22
Market Capitalization1,820.241,820.241,389.78777.18671.08304.341,022.301,394.58554.58

Income statement, quarterly

Currency USD, millions
Metric2026S22026S12025S22025S12024S22024S12015S1
Total Revenue69.1451.4314.053.162.513.39-9.61
Cost of Goods Sold Incl. D&A10.338.8524.19-12.668.976.75-11.76
Gross Profit58.8142.58-10.1515.81-6.45-3.36--2.15
Selling, General and Administrative Excl. Other79.1873.6031.9735.7524.8424.13-46.82
Research and Development51.5246.2414.1620.6512.7012.65-32.09
Other Operating Expense0.000.000.000.480.04--0.00
Operating Income-20.37-31.02-42.12-20.42-31.33-27.49--48.97
Interest Expense8.7615.1412.1410.8312.6810.32--
Unusual Expense-10.20-3.153.5716.2813.00-4.10-9.56
Net Income Before Taxes-17.23-39.79-54.19-47.72-56.34-32.64--48.27
Income Taxes0.170.450.040.21-0.95-0.10--3.10
Consolidated Net Income-17.40-40.23-54.23-47.93-55.39-32.54--45.17
Net Income From Continuing Operations-17.40-40.23-54.23-47.93-55.39-32.54--45.17
Net Income-17.40-40.23-54.23-47.93-55.39-32.54--45.17
EPS (Recurring)-0.19-0.33-0.41-0.32-0.43-0.42--1.11
EPS (Basic, Before Extraordinaries)-0.13-0.31-0.43-0.42-0.51-0.38--1.31
EPS (Diluted)-0.13-0.31-0.43-0.42-0.51-0.38--1.31
EBITDA-16.08-26.70-37.80-18.34-29.11-25.04--48.20
Non-Operating Income (Expense)1.713.223.65-0.190.681.07-10.27
Stock Option Compensation Expense4.056.384.8410.622.57--2.33
Price To Sales Ratio14.5535.6080.54398.99125.59--67.77
Gross Margin85.0682.80-72.25501.05-256.84-99.11--22.43
Operating Margin-29.47-60.31-299.86-647.05-1,246.78-811.30--509.80
Net Margin-25.16-78.22-386.04-1,518.82-2,204.34-960.42--470.19
Shares Outstanding129.67128.85127.99115.24114.12101.48-34.54
Market Capitalization1,820.242,314.421,389.782,269.63777.18188.79-1,226.85

Balance sheet, annual

Currency USD, millions
Metric2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments102.91161.5562.9671.3260.45136.88129.3350.4338.01
Short Term Receivables57.6614.8720.957.004.404.841.574.0650.12
Inventories28.1122.250.000.000.000.000.000.000.00
Other Current Assets8.815.692.553.344.996.505.658.0412.94
Total Current Assets197.49204.3586.4681.6669.84148.23136.5562.52101.07
Net Property, Plant & Equipment8.015.823.846.499.9612.1410.270.831.08
Total Investments and Advances0.001.391.011.761.762.081.872.323.03
Intangible Assets566.37571.83575.74577.18578.65580.55581.60583.13584.61
Deferred Tax Assets----88.2480.1679.0965.4356.57
Other Assets1.201.302.102.331.931.723.313.322.65
Total Assets773.08784.68669.15669.41750.38824.88812.70717.54749.02
Short Term Debt Incl. Current Port. of LT Debt13.6356.8416.4910.018.2055.9735.9714.010.00
Accounts Payable34.5119.087.0720.1423.0819.6024.9713.0618.92
Income Tax Payable------0.100.100.15
Other Current Liabilities32.9826.7149.6911.8220.0918.7129.2017.265.08
Total Current Liabilities81.11102.6373.2441.9851.3794.2790.2444.4324.15
Long Term Debt113.7171.32102.44106.4898.7049.5363.3467.2859.40
Provision for Risks Charges7.3610.7910.6216.6112.5217.0227.5648.3342.96
Deferred Tax Liabilities----88.2480.1679.7376.4576.50
Other Liabilities2.502.502.502.502.502.502.500.000.00
Total Liabilities204.67187.24188.80167.58253.34243.48263.37236.49203.01
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity568.40597.44480.35501.84497.04581.40549.33481.05546.01
Total Shareholders Equity568.40597.44480.35501.84497.04581.40549.33481.05546.01
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity568.40597.44480.35501.84497.04581.40549.33481.05546.01
Total Liabilities & Stockholders Equity773.08784.68669.15669.41750.38824.88812.70717.54749.02
Book Value Per Share4.384.674.215.857.258.518.979.2110.80
Tangible Book Value Per Share0.020.20-0.84-0.88-1.190.01-0.53-1.95-0.76
Full-Time Employees10881738377831028381
Price to Book Ratio3.192.721.361.340.611.762.541.110.98
Return on Assets-7.42-14.03-13.19-11.48-11.60-12.11-10.19-12.25-4.76
Return on Equity-9.91-18.92-17.98-16.32-16.94-17.54-15.13-17.49-6.64
Return on Invested Capital-8.47-15.25-15.15-13.40-15.33-15.72-12.72-16.38-5.83
Quick Ratio2.091.771.181.951.361.571.511.414.19
Current Ratio2.431.991.181.951.361.571.511.414.19

Cash flow, annual

Currency USD, millions
MetricTTM2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-57.69-57.76-101.97-88.28-81.52-91.35-99.18-77.94-89.80
Depreciation8.618.626.394.684.094.384.283.672.14
Other Funds (Non Cash)5.195.2041.8130.4911.1310.47-2.9114.0318.39
Funds from Operations-43.27-43.32-53.44-53.30-66.51-76.73-98.63-69.66-78.23
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-23.89-23.92-3.04-2.64-2.464.87-8.4513.2920.44
Income Taxes Payable-0.001.271.50-2.38-0.001.501.73
Cash from Operating Activities-67.17-67.24-56.47-55.94-68.97-71.87-107.08-56.37-57.79
Capital Expenditures-0.90-0.90-0.73-0.33-0.31-0.23-1.65-2.25-0.28
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments-0.13-0.130.240.230.120.000.000.000.00
Purchase of Investments-0.13-0.130.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.240.230.120.000.000.000.00
Other Uses0.000.000.000.000.000.000.00-1.03-0.72
Other Sources0.000.000.610.000.000.000.000.000.00
Cash from Investing Activities-1.03-1.030.12-0.10-0.19-0.23-1.65-3.27-1.00
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock13.7713.78163.4461.2783.378.07117.85138.6729.65
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock13.7713.78163.4461.2783.378.07117.85138.6729.65
Proceedsfrom Stock Options2.092.09156.6261.2783.378.07104.83138.6729.65
Issuance or Reduction of Debt, Net-3.96-3.96-7.81-10.040.00-9.070.000.0041.96
Change in Long Term Debt-3.96-3.96-7.81-10.040.00-9.070.000.0041.96
Issuance of Long Term Debt121.44121.580.000.000.0046.390.000.5143.57
Reduction of Long Term Debt-125.40-125.54-7.81-10.040.00-55.460.00-0.51-1.61
Net Financing Active Other Cash Flow0.320.320.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities7.817.82153.6947.7080.15-3.79114.89137.0471.61
Exchange Rate Effect1.551.551.09-0.06-0.17-0.551.421.50-0.15
Net Change in Cash-58.83-58.9098.42-8.3910.82-76.437.5878.9012.66
Free Cash Flow-68.00-68.08-57.15-56.21-69.23-72.02-108.73-58.46-58.07
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.620.33-0.19-0.21-0.23-0.82-9.41-8.96

Balance sheet, quarterly

Currency USD, millions
Metric2026S22026S12025S22025S12024S22024S1
Cash & Short Term Investments102.91129.97161.5538.0362.9677.55
Short Term Receivables57.6643.3014.873.0020.954.00
Inventories28.1121.6622.2524.190.000.00
Other Current Assets8.817.545.694.462.553.60
Total Current Assets197.49202.48204.3569.6886.4685.15
Net Property, Plant & Equipment8.018.285.826.223.845.50
Total Investments and Advances0.001.551.391.211.010.83
Intangible Assets566.37568.80571.83574.88575.74576.56
Other Assets1.201.191.301.332.102.24
Total Assets773.08782.31784.68653.32669.15670.28
Short Term Debt Incl. Current Port. of LT Debt13.6369.1256.8419.8916.4911.38
Accounts Payable34.5127.1119.0811.867.0710.76
Other Current Liabilities32.9831.8326.7141.0049.699.22
Total Current Liabilities81.11128.07102.6372.7573.2431.37
Long Term Debt113.7166.0271.32106.22102.44110.61
Other Liabilities2.5013.532.502.502.502.50
Total Liabilities204.67207.62187.24192.06188.80161.55
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity568.40574.68597.44461.26480.35508.73
Total Shareholders Equity568.40574.68597.44461.26480.35508.73
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity568.40574.68597.44461.26480.35508.73
Total Liabilities & Stockholders Equity773.08782.31784.68653.32669.15670.28
Book Value Per Share4.384.464.674.004.215.01
Tangible Book Value Per Share0.020.050.20-0.99-0.84-0.67
Price to Book Ratio3.193.862.724.701.360.38
Return on Assets-7.40-13.16-14.05-15.61--
Return on Equity-9.89-18.24-18.96-21.30--
Return on Invested Capital-2.55-6.28-8.11-8.45-9.50-5.25
Quick Ratio2.091.411.770.631.182.71
Current Ratio2.431.581.990.961.182.71

Cash flow, quarterly

Currency USD, millions
Metric2026S22026S12025S22025S12024S22024S1
Net Income-17.46-40.23-54.24-47.93-55.37-32.54
Depreciation4.304.324.322.082.222.44
Other Funds (Non Cash)-10.6315.8219.8922.0125.494.87
Funds from Operations-23.62-19.65-29.91-23.63-27.75-25.32
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-6.04-17.86-2.65-0.392.00-4.63
Cash from Operating Activities-29.66-37.51-32.57-24.02-25.75-29.96
Capital Expenditures-0.42-0.48-0.62-0.11-0.07-0.20
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-0.00-0.130.120.120.120.12
Purchase of Investments-0.00-0.130.000.000.000.00
Sale Or Maturity of Investments0.000.000.120.120.120.12
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.610.000.00
Cash from Investing Activities-0.42-0.61-0.510.63-0.01-0.09
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock4.379.40161.092.6823.8937.13
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock4.379.40161.092.6823.8937.13
Proceedsfrom Stock Options0.651.43156.96-0.0223.8937.13
Issuance or Reduction of Debt, Net-5.661.70-5.22-2.61-9.990.00
Change in Long Term Debt-5.661.70-5.22-2.61-9.990.00
Issuance of Long Term Debt50.2871.160.000.000.000.00
Reduction of Long Term Debt-55.94-69.46-5.22-2.61-9.990.00
Net Financing Active Other Cash Flow4.30-3.980.000.000.000.00
Other Financing Activities Uses4.30-4.300.000.000.000.00
Cash from Financing Activities1.835.98154.90-0.9012.5234.98
Exchange Rate Effect1.050.501.73-0.64-1.351.30
Net Change in Cash-27.20-31.63123.55-24.93-14.596.24
Free Cash Flow-30.07-37.93-33.14-24.12-25.81-30.16

Revenue breakdown

Biological Products, (No Diagnostic Substances)2025: 17.20M
Australia2025: 17.20M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-302.79%3.6M128.3M234.30K
2026-10-152.55%3.3M128.3M224.76K
2026-09-302.58%3.3M128.3M230.06K
2026-09-152.58%3.3M128.3M229.44K
2026-08-312.46%3.2M128.3M225.44K
2026-08-142.35%3.0M128.3M215.97K
2026-07-312.47%3.2M128.3M215.76K
2026-07-152.44%3.1M128.3M192.93K
2026-06-302.42%3.1M128.3M194.13K
2026-06-152.42%3.1M128.3M209.77K
2026-05-292.39%3.1M128.3M245.50K
2026-05-152.29%2.9M128.3M246.66K
2026-04-302.26%2.9M128.3M256.18K
2026-04-152.38%3.0M128.3M260.90K
2026-03-312.47%3.2M128.3M255.22K
2026-03-132.50%3.2M128.3M239.59K
2026-02-272.17%2.8M128.3M217.14K
2026-02-132.10%2.7M128.3M218.23K
2026-01-302.09%2.7M128.3M212.70K
2026-01-152.06%2.6M128.3M211.02K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call7.004.709.400.009.1810.000.000.880-0.1630.004
call8.003.808.400.007.9540.000.000.855-0.1590.005
call9.002.807.300.006.6910.000.000.827-0.1530.006
call10.001.806.300.005.7600.000.000.794-0.1440.006
call11.000.905.300.004.9380.000.000.755-0.1340.007
call12.000.205.005.505.1611.000.000.703-0.1190.007
call13.000.055.000.505.65633.000.000.716-0.2670.007
call14.000.005.000.356.0921.000.000.675-0.2600.008
call15.000.002.000.256.4437130.000.661-0.2790.008
call16.000.052.000.853.22526.000.000.485-0.1560.009
call17.000.002.000.253.5401,7450.000.462-0.1700.009
call18.000.005.000.003.8100.000.000.444-0.1820.009
call19.000.005.000.003.9500.000.000.430-0.1890.009
call20.000.005.000.204.30955.000.000.417-0.2030.008
call21.000.005.000.004.4790.000.000.407-0.2090.008
call25.000.005.000.005.1110.000.000.377-0.2360.008
call30.000.005.000.005.7940.000.000.354-0.2620.008
put7.000.005.000.006.7210.000.00-0.118-0.1610.004
put8.000.005.000.005.7720.000.00-0.142-0.1570.005
put9.000.005.000.004.9500.000.00-0.169-0.1510.006
put10.000.005.000.004.2200.000.00-0.201-0.1430.006
put11.000.005.000.002.7050.000.00-0.222-0.0940.007
put12.000.001.500.922.66120.000.00-0.281-0.1080.007
put13.000.055.000.156.7512.000.00-0.284-0.2660.007
put14.000.155.000.705.84941.000.00-0.325-0.2590.008
put15.000.005.001.404.9991320.00-0.475-0.1440.009
put16.000.305.003.904.14712.000.00-0.516-0.1540.009
put17.000.855.502.753.8893.000.00-0.539-0.1690.009
put18.001.756.404.954.0611.000.00-0.556-0.1800.009
put19.002.807.400.004.2970.000.00-0.571-0.1900.009
put20.003.808.400.004.5450.000.00-0.583-0.2010.008
put21.004.709.400.004.8120.000.00-0.593-0.2100.008
put25.008.7013.300.005.3990.000.00-0.622-0.2380.008
put30.0013.8018.300.006.0190.000.00-0.644-0.2600.008

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-036-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-02SEC
2026-10-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-29SEC
2026-10-166-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-16SEC
2026-10-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-14SEC
2026-10-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-13SEC
2026-09-246-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-24SEC
2026-08-276-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-27SEC
2026-08-2720-FRegistration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer.2026-06-30SEC
2026-08-256-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-25SEC
2026-08-246-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-24SEC
2026-08-186-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-17SEC
2026-07-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-30SEC
2026-07-216-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-21SEC
2026-07-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-14SEC
2026-07-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-14SEC
2026-07-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-10SEC
2026-07-094Statement of changes in beneficial ownership of securities2026-07-07SEC
2026-07-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-01SEC
2026-06-256-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-25SEC
2026-06-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-10SEC
2026-04-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-30SEC
2026-04-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-29SEC
2026-04-293Initial statement of beneficial ownership of securities2026-03-18SEC
2026-04-176-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-17SEC
2026-04-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-15SEC
2026-04-134Statement of changes in beneficial ownership of securities2026-04-09SEC
2026-04-104Statement of changes in beneficial ownership of securities2026-04-09SEC
2026-04-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-08SEC
2026-04-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-08SEC
2026-04-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-08SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-0437.53M600
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
MORGAN STANLEY0.56%
BlackRock, Inc.0.51%
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.35%
GOLDMAN SACHS GROUP INC0.31%
BNP Paribas Asset Management Holding S.A.0.20%
UBS Group AG0.15%
Arax Advisory Partners0.13%
GROUP ONE TRADING LLC0.10%
BANK OF AMERICA CORP /DE/0.08%
Penbrook Management LLC0.07%

Funds

Fund% owned
iShares Biotechnology ETF0.38%
Fidelity Nasdaq Composite Index Fund0.01%
ActivePassive International Equity ETF0.01%
Invesco NASDAQ Future Gen 200 ETF0.01%
Steward Values Enhanced International Fund0.01%
Invesco Nasdaq Biotechnology ETF0.00%
ProShares Ultra Nasdaq Biotechnology0.00%
Blackstone Alternative Multi-Strategy Fund0.00%
Multi-Manager Directional Alternative Strategies Fund-0.01%
Boston Partners Long/Short Research Fund-0.02%

OakChart. MESO. Cached 15 minutes.